767 related articles for article (PubMed ID: 32979231)
1. Efficacy and safety of a sodium-glucose co-transporter-2 inhibitor versus placebo as an add-on therapy for people with type 2 diabetes inadequately treated with metformin and a dipeptidyl peptidase-4 inhibitor: a systematic review and meta-analysis of randomised controlled trials.
De Buitléir C; O' Connor E; Satti MM; Shaw J; Liew A
Diabet Med; 2021 Feb; 38(2):e14409. PubMed ID: 32979231
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as monotherapy or add-on to metformin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
Wang Z; Sun J; Han R; Fan D; Dong X; Luan Z; Xiang R; Zhao M; Yang J
Diabetes Obes Metab; 2018 Jan; 20(1):113-120. PubMed ID: 28656707
[TBL] [Abstract][Full Text] [Related]
3. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Lo C; Toyama T; Oshima M; Jun M; Chin KL; Hawley CM; Zoungas S
Cochrane Database Syst Rev; 2020 Jul; 8(8):CD009966. PubMed ID: 32803882
[TBL] [Abstract][Full Text] [Related]
4. Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.
Lo C; Toyama T; Wang Y; Lin J; Hirakawa Y; Jun M; Cass A; Hawley CM; Pilmore H; Badve SV; Perkovic V; Zoungas S
Cochrane Database Syst Rev; 2018 Sep; 9(9):CD011798. PubMed ID: 30246878
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular safety and efficacy of metformin-SGLT2i versus metformin-sulfonylureas in type 2 diabetes: systematic review and meta-analysis of randomized controlled trials.
Gebrie D; Getnet D; Manyazewal T
Sci Rep; 2021 Jan; 11(1):137. PubMed ID: 33420333
[TBL] [Abstract][Full Text] [Related]
6. The safety of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter 2 (SGLT-2) inhibitors added to metformin background therapy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
Kawalec P; Mikrut A; Łopuch S
Diabetes Metab Res Rev; 2014 May; 30(4):269-83. PubMed ID: 24829965
[TBL] [Abstract][Full Text] [Related]
7. Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial.
Pratley RE; Eldor R; Raji A; Golm G; Huyck SB; Qiu Y; Sunga S; Johnson J; Terra SG; Mancuso JP; Engel SS; Lauring B
Diabetes Obes Metab; 2018 May; 20(5):1111-1120. PubMed ID: 29266675
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis.
Wu D; Li L; Liu C
Diabetes Obes Metab; 2014 Jan; 16(1):30-7. PubMed ID: 23803146
[TBL] [Abstract][Full Text] [Related]
9. Incretin mimetics and sodium-glucose co-transporter 2 inhibitors as monotherapy or add-on to metformin for treatment of type 2 diabetes: a systematic review and network meta-analysis.
Jia S; Wang Z; Han R; Zhang Z; Li Y; Qin X; Zhao M; Xiang R; Yang J
Acta Diabetol; 2021 Jan; 58(1):5-18. PubMed ID: 32514989
[TBL] [Abstract][Full Text] [Related]
10. Sodium-Glucose Co-Transporter 2 Inhibitors Compared with Sulfonylureas in Patients with Type 2 Diabetes Inadequately Controlled on Metformin: A Meta-Analysis of Randomized Controlled Trials.
Chen Z; Li G
Clin Drug Investig; 2019 Jun; 39(6):521-531. PubMed ID: 31041606
[TBL] [Abstract][Full Text] [Related]
11. Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin.
Rosenstock J; Mathieu C; Chen H; Garcia-Sanchez R; Saraiva GL
Arch Endocrinol Metab; 2018 Aug; 62(4):424-430. PubMed ID: 30304106
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Triple Therapy with SGLT-2 Inhibitor, DPP-4 Inhibitor, and Metformin in Type 2 Diabetes: A Meta-Analysis.
Li M; Wang S; Wang X
Altern Ther Health Med; 2023 Jul; 29(5):320-326. PubMed ID: 37171944
[TBL] [Abstract][Full Text] [Related]
13. Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I Study.
Roussel R; Duran-García S; Zhang Y; Shah S; Darmiento C; Shankar RR; Golm GT; Lam RLH; O'Neill EA; Gantz I; Kaufman KD; Engel SS
Diabetes Obes Metab; 2019 Apr; 21(4):781-790. PubMed ID: 30393950
[TBL] [Abstract][Full Text] [Related]
14. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
Lingvay I
Endocr Pract; 2017 Jul; 23(7):831-840. PubMed ID: 28332871
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24-week, multicentre, randomized, double-blind, placebo-controlled study (TROICA study).
Ahn CH; Han KA; Yu JM; Nam JY; Ahn KJ; Oh TK; Lee HW; Lee DH; Kim J; Chung CH; Park TS; Kim BJ; Park SW; Park HK; Lee KJ; Kim SW; Park JH; Ko KP; Kim CH; Lee H; Jang HC; Park KS
Diabetes Obes Metab; 2017 May; 19(5):635-643. PubMed ID: 28026912
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of dapagliflozin plus saxagliptin vs monotherapy as added to metformin in patients with type 2 diabetes: A meta-analysis.
Zhuang Y; Song J; Ying M; Li M
Medicine (Baltimore); 2020 Jul; 99(30):e21409. PubMed ID: 32791755
[TBL] [Abstract][Full Text] [Related]
17. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.
Karagiannis T; Paschos P; Paletas K; Matthews DR; Tsapas A
BMJ; 2012 Mar; 344():e1369. PubMed ID: 22411919
[TBL] [Abstract][Full Text] [Related]
18. Reduction in HbA1c with SGLT2 inhibitors vs. DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1c: A systematic review of randomized controlled trials.
Scheen AJ
Diabetes Metab; 2020 Jun; 46(3):186-196. PubMed ID: 32007623
[TBL] [Abstract][Full Text] [Related]
19. Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis.
Min SH; Yoon JH; Hahn S; Cho YM
Diabetes Metab Res Rev; 2017 Jan; 33(1):. PubMed ID: 27155214
[TBL] [Abstract][Full Text] [Related]
20. Combination of sodium-glucose cotransporter 2 inhibitor and dipeptidyl peptidase-4 inhibitor in type 2 diabetes: a systematic review with meta-analysis.
Min SH; Yoon JH; Moon SJ; Hahn S; Cho YM
Sci Rep; 2018 Mar; 8(1):4466. PubMed ID: 29535389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]